Ji Hyeon Joo1, Jin-Hong Park1, Jin Cheon Kim2, Chang Sik Yu2, Seok-Byung Lim2, In Ja Park2, Tae Won Kim3, Yong Sang Hong3, Kyu-Pyo Kim3, Sang Min Yoon1, Jongmoo Park4, Jong Hoon Kim5. 1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 2. Department of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 4. Dangjin Public Health Center, Dangjin-si, Chungcheongnam-do, South Korea. 5. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: jhkim2@amc.seoul.kr.
Abstract
PURPOSE: To evaluate the effective dose and patterns of recurrence after stereotactic body radiation therapy (SBRT) for hepatic metastases that arise from colorectal cancer. METHODS AND MATERIALS: A cohort of 70 patients with 103 colorectal liver metastases were treated with SBRT at a single institution. The prescribed doses were 45 to 60 Gy in 3 to 4 fractions, but these were modified according to the tolerance of the adjacent normal tissue. To allow for dose comparisons, a biological equivalent dose was calculated. RESULTS: The median follow-up period was 34.2 months (range, 5.3-121.8 months). The 2-year overall survival and progression-free survival rates were 75% and 35%, respectively. In subgroups, the 2-year local control rates for biological equivalent dose ≤80 Gy (group 1), 100 to 112 Gy (group 2), and ≥132 Gy (group 3) were 52%, 83%, and 89%, respectively. Cox proportional hazards model revealed a significant difference between groups (hazard ratio 0.44, P=.03 for group 2; hazard ratio 0.17, P=.17 for group 3; P=.01 for total). The major pattern of failure was a new liver metastasis out of the SBRT field. There was no grade ≥3 toxicity. CONCLUSIONS: Stereotactic body radiation therapy of liver metastases derived from colorectal cancer offers a locally effective treatment without significant complications. Longer local control can be expected if higher doses are used. Further studies will be needed to compare the efficacies of SBRT with those of surgical resection or radiofrequency ablation.
PURPOSE: To evaluate the effective dose and patterns of recurrence after stereotactic body radiation therapy (SBRT) for hepatic metastases that arise from colorectal cancer. METHODS AND MATERIALS: A cohort of 70 patients with 103 colorectal liver metastases were treated with SBRT at a single institution. The prescribed doses were 45 to 60 Gy in 3 to 4 fractions, but these were modified according to the tolerance of the adjacent normal tissue. To allow for dose comparisons, a biological equivalent dose was calculated. RESULTS: The median follow-up period was 34.2 months (range, 5.3-121.8 months). The 2-year overall survival and progression-free survival rates were 75% and 35%, respectively. In subgroups, the 2-year local control rates for biological equivalent dose ≤80 Gy (group 1), 100 to 112 Gy (group 2), and ≥132 Gy (group 3) were 52%, 83%, and 89%, respectively. Cox proportional hazards model revealed a significant difference between groups (hazard ratio 0.44, P=.03 for group 2; hazard ratio 0.17, P=.17 for group 3; P=.01 for total). The major pattern of failure was a new liver metastasis out of the SBRT field. There was no grade ≥3 toxicity. CONCLUSIONS: Stereotactic body radiation therapy of liver metastases derived from colorectal cancer offers a locally effective treatment without significant complications. Longer local control can be expected if higher doses are used. Further studies will be needed to compare the efficacies of SBRT with those of surgical resection or radiofrequency ablation.
Authors: R Vera; E González-Flores; C Rubio; J Urbano; M Valero Camps; J J Ciampi-Dopazo; J Orcajo Rincón; V Morillo Macías; M A Gomez Braco; G Suarez-Artacho Journal: Clin Transl Oncol Date: 2019-07-29 Impact factor: 3.405
Authors: V Dell'Acqua; A Surgo; F Kraja; J Kobiela; Maria Alessia Zerella; P Spychalski; S Gandini; C M Francia; D Ciardo; C Fodor; A M Ferrari; G Piperno; F Cattani; S Vigorito; F Pansini; W Petz; R Orecchia; M C Leonardi; B A Jereczek-Fossa Journal: Clin Exp Metastasis Date: 2019-06-04 Impact factor: 5.150
Authors: Alex R Coffman; Daniel C Sufficool; Joseph I Kang; Chung-Tsen Hsueh; Sasha Swenson; Patrick Q McGee; Gayathri Nagaraj; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2021-08
Authors: Joseph I Kang; Daniel C Sufficool; Chung-Tsen Hsueh; Andrew J Wroe; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2019-02
Authors: Fabian Weykamp; Philipp Hoegen; Sebastian Klüter; C Katharina Spindeldreier; Laila König; Katharina Seidensaal; Sebastian Regnery; Jakob Liermann; Carolin Rippke; Stefan A Koerber; Carolin Buchele; Jürgen Debus; Juliane Hörner-Rieber Journal: Front Oncol Date: 2021-06-09 Impact factor: 6.244